Generic Triferic AVNU Availability
Last updated on July 7, 2021.
See also: Generic Triferic
TRIFERIC AVNU (ferric pyrophosphate citrate - solution;intravenous)
Manufacturer: ROCKWELL MEDICAL INC
Approval date: March 27, 2020
Strength(s): 6.75MG IRON/4.5ML (1.5MG IRON/ML) [RLD]
Has a generic version of Triferic AVNU been approved?
No. There is currently no therapeutically equivalent version of Triferic AVNU available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Triferic AVNU. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
Issued: October 19, 2010
Inventor(s): McCall, Jr.; William S.
Assignee(s): Rockwell Medical Technologies, Inc.
A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.
Patent expiration dates:
- April 17, 2029✓✓
- April 17, 2029
More about Triferic AVNU (ferric pyrophosphate)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Drug class: iron products
- Other brands
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.